- Home
- RPRX vs ILMN Comparison
RPRX vs ILMN Comparison
Compare RPRX & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- ILMN
- Stock Information
- Founded
- RPRX 1996
- ILMN 1998
- Country
- RPRX United States
- ILMN United States
- Employees
- RPRX N/A
- ILMN N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- ILMN Medical Specialities
- Sector
- RPRX Health Care
- ILMN Health Care
- Exchange
- RPRX Nasdaq
- ILMN Nasdaq
- Market Cap
- RPRX 14.2B
- ILMN 15.9B
- IPO Year
- RPRX 2020
- ILMN 2000
- Fundamental
- Price
- RPRX $33.10
- ILMN $79.58
- Analyst Decision
- RPRX Strong Buy
- ILMN Buy
- Analyst Count
- RPRX 4
- ILMN 18
- Target Price
- RPRX $42.50
- ILMN $138.22
- AVG Volume (30 Days)
- RPRX 3.9M
- ILMN 1.9M
- Earning Date
- RPRX 05-08-2025
- ILMN 05-08-2025
- Dividend Yield
- RPRX 2.66%
- ILMN 3.90%
- EPS Growth
- RPRX 37.42
- ILMN N/A
- EPS
- RPRX 2.45
- ILMN N/A
- Revenue
- RPRX $2,263,576,000.00
- ILMN $4,372,000,000.00
- Revenue This Year
- RPRX $31.30
- ILMN N/A
- Revenue Next Year
- RPRX $5.82
- ILMN $4.51
- P/E Ratio
- RPRX $13.52
- ILMN N/A
- Revenue Growth
- RPRX 1.12
- ILMN N/A
- 52 Week Low
- RPRX $24.05
- ILMN $68.70
- 52 Week High
- RPRX $34.20
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- RPRX 57.01
- ILMN 53.52
- Support Level
- RPRX $31.97
- ILMN $73.86
- Resistance Level
- RPRX $33.00
- ILMN $79.22
- Average True Range (ATR)
- RPRX 0.71
- ILMN 2.60
- MACD
- RPRX 0.08
- ILMN 0.84
- Stochastic Oscillator
- RPRX 60.08
- ILMN 88.40
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.